Investigators conducted a cross-sectional online survey of U.S. adults in spring 2026 and enrolled 1,069 respondents. The study used a non-probability sampling approach, and participants were randomized to one of two framing conditions: a stated-price condition specifying $20, or an open 'any amount of money' condition. Primary outcomes were binary acceptability judgments — yes or no — for a range of pharmacist-provided and related health services. The team also collected demographic characteristics and measures of trust in pharmacists as secondary outcomes.
The authors reported that the $20 stated-price frame produced higher agreement overall than the unspecified 'any amount' frame. The survey instrument, recruitment platforms, and response-rate details were not reported in the source abstract; those methodological specifics therefore cannot be summarized here. Institutional review board approvals were noted from Western New England University and the University of California, San Diego.
Responses were heterogeneous across service types. In the $20 stated-price condition, the highest acceptability was seen for osteoporosis screening (75.8%) and for travel-related vaccines (69.0%). These services, not traditionally billed out-of-pocket at community pharmacy counters, attracted relatively strong willingness to pay when a concrete price was presented.
By contrast, acceptability was lowest for services that respondents may expect as part of routine medication-related care or urgent wound management. In the $20 arm, antibiotic use consultation had 23.9% agreement and wound care had 32.1% agreement. These low rates indicate that consumers distinguish between preventive or episodic services and those perceived as core, ongoing, or urgent pharmacy functions.
The pattern suggests that public willingness to pay is sensitive both to the nature of the clinical service and to price framing. Data indicated that framing a concrete $20 fee produced systematically higher acceptability than asking whether people would pay an unspecified amount, implying that specific pricing signals matter for consumer judgments.
The survey identified several respondent characteristics associated with payment acceptability. Older respondents were less likely to view self-payment as acceptable. Hispanic respondents also showed lower likelihood of accepting out-of-pocket payments for the services queried. Men were more likely to endorse acceptability compared with women. Importantly, respondents reporting greater pharmacist trust were more likely to view self-payment as acceptable.
Authors reported these associations but the source did not provide full model coefficients, confidence intervals, or p-values in the abstract. The survey captured trust designations as a secondary measure; investigators observed that trust in the pharmacist correlated with willingness to pay, suggesting that payer acceptance may depend on patient–pharmacist relationships and perceived clinical value.
These findings may guide which services pharmacies consider packaging as fee-for-service offerings and which populations may require targeted communication or subsidization strategies to avoid widening disparities.
The authors used a non-probability, online sampling approach; this design choice limits claims about representativeness of the U.S. adult population. The source did not report survey response rates, recruitment platforms, or detailed psychometric properties of the instrument in the abstract, so potential biases from sampling and measurement cannot be fully assessed here. The cross-sectional design captures stated preferences at a single time point only, and revealed willingness-to-pay in real-world settings may differ from survey responses.
Several implementation questions remain unanswered by the source document. The survey did not report on how respondents interpreted specific service scopes (for example, what content they expected from an 'antibiotic use consultation'), nor did it present alternative price points beyond $20 or describe incremental willingness at other fees. The authors noted IRB approvals and that all data are published in the manuscript; further methodological detail would be required to evaluate external validity, subgroup sample sizes, and the strength of the reported associations.
Regulators, payers, and pharmacy operators will likely need additional, prospectively collected data on actual purchasing behavior, differential access across demographic groups, and cost-effectiveness of fee-for-service offerings to translate these survey results into policy or practice decisions.
Limitations documented in the source therefore center on sampling design and the absence of detailed procedural reporting in the abstract, and these gaps define clear next steps for research and implementation pilots.